Skip to Content

Binimetinib Approval Status

  • FDA approved: No
  • Generic name: binimetinib
  • Company: Array BioPharma
  • Treatment for: Melanoma, Metastatic

Binimetinib is a late-stage small molecule MEK inhibitor in development for the treatment of advanced NRAS-mutant melanoma.

Development Status and FDA Approval Process for binimetinib

Mar 19, 2017Array BioPharma Announces Withdrawal of NDA for Binimetinib Monotherapy for the Treatment of NRAS-Mutant Melanoma
Sep  1, 2016Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma
Jun 30, 2016Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA
Sep 28, 2015Clinical Data Presented On Binimetinib And Encorafenib In Melanoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.